Publications by authors named "Richard F Riedel"

54Publications

Academic-Practice Partnership for Caregiver Training and Support: The Duke Elder Family/Caregiver Training (DEFT) Center.

N C Med J 2020 Jul-Aug;81(4):221-227

associate professor, Duke University School of Nursing, Durham, North Carolina; core investigator, Durham Veterans Affairs Health Care System Geriatric Research, Education, and Clinical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18043/ncm.81.4.221DOI Listing
July 2020

Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology.

Expert Rev Anticancer Ther 2020 01 25;20(1):5-8. Epub 2019 Dec 25.

Division of Medical Oncology, Department of Medicine, Duke University Health System, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2020.1708198DOI Listing
January 2020

Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread.

Front Oncol 2019 28;9:1322. Epub 2019 Nov 28.

The Preston Robert Tisch Brain Tumor Center, Duke University Health System, Durham, NC, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.01322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892774PMC
November 2019

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

J Clin Oncol 2019 06 23;37(16):1424-1431. Epub 2019 Apr 23.

16 Monter Cancer Center, Northwell Health, Lake Success, NY, and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.02374DOI Listing
June 2019

Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration.

Authors:
Richard F Riedel

Lancet Oncol 2019 01 18;20(1):14-15. Epub 2018 Dec 18.

Duke Cancer Institute, Durham, NC 27710, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30745-9DOI Listing
January 2019

Sorafenib for Advanced and Refractory Desmoid Tumors.

N Engl J Med 2018 12;379(25):2417-2428

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center (M.M.G., W.D.T., N.H., N.P.A., R.A.L., Y.M., R.Y.) and Columbia University Vagellos College of Physicians and Surgeons and New York Presbyterian Hospital (L.H.S., G.K.S.), New York, and Northwell Cancer Institute and Cold Spring Harbor Laboratory, Lake Success (R.G.M.) - all in New York; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN (M.R.M.); Washington University School of Medicine, St. Louis (B.A.V.T.); M.D. Anderson Cancer Center, University of Texas, Houston (V.R.); Mayo Clinic in Florida, Jacksonville (S.A.); Yale University, New Haven, CT (H.A.D.); University Health Network Princess Margaret Cancer Centre, Toronto (A.A.G.); University of Iowa-Holden Comprehensive Cancer Center, Iowa City (M.M.M.); University of Alabama at Birmingham Cancer Center, Birmingham (R.M.C.); Fox Chase Cancer Center, Philadelphia (S.M.); Georgetown University, Lombardi Comprehensive Cancer Center, Washington, DC (M.J.P.); Duke Cancer Institute, Duke University Medical Center, Durham (R.F.R.), and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill (E.B.) - both in North Carolina; Dayton National Cancer Institute Community Oncology Research Program, Dayton, OH (T.S.); National Cancer Institute, Bethesda, MD (J.J.W.); and the Alliance Statistics and Data Center, Mayo Clinic, Scottsdale, AZ (A.C.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447029PMC
December 2018

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.

Cancers (Basel) 2018 Nov 1;10(11). Epub 2018 Nov 1.

Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/10/11/417
Publisher Site
http://dx.doi.org/10.3390/cancers10110417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267101PMC
November 2018

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.

Cancer 2018 10 3;124(19):3819-3829. Epub 2018 May 3.

Department of Pharmacology and Cancer Biology, Duke University Health System, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31517
Publisher Site
http://dx.doi.org/10.1002/cncr.31517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215523PMC
October 2018

Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service.

J Oncol Pract 2017 09 10;13(9):e738-e748. Epub 2017 Aug 10.

Duke University Health System; Duke University School of Medicine, Durham NC; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.022749DOI Listing
September 2017

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Cancer Chemother Pharmacol 2017 03 25;79(3):611-619. Epub 2017 Feb 25.

Duke Cancer Institute, Duke University Medical Center, Seeley G. Mudd Building, 10 Bryan Searle Drive, Box 3052, Durham, NC, 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3256-2DOI Listing
March 2017

Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib.

Case Rep Oncol Med 2015 28;2015:317493. Epub 2015 Jan 28.

Department of Pathology, Duke University, DUMC Box 3712, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/317493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324915PMC
February 2015

Chemotherapy in soft-tissue sarcoma: where do we go from here?

Oncology (Williston Park) 2015 Jan;29(1):50, 52-3

View Article

Download full-text PDF

Source
January 2015

Gastrointestinal stromal tumors, version 2.2014.

J Natl Compr Canc Netw 2014 Jun;12(6):853-62

From Fox Chase Cancer Center; Huntsman Cancer Institute at the University of Utah; The University of Texas MD Anderson Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; Roswell Park Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; UCSF Helen Diller Family Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; City of Hope Comprehensive Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/12/6/853.full.pdf
Web Search
http://dx.doi.org/10.6004/jnccn.2014.0080DOI Listing
June 2014

Soft tissue sarcoma, version 2.2014.

J Natl Compr Canc Netw 2014 Apr;12(4):473-83

From 1Fox Chase Cancer Center; 2Huntsman Cancer Institute at the University of Utah; 3The University of Texas MD Anderson Cancer Center; 4UC San Diego Moores Cancer Center; 5Moffitt Cancer Center; 6Memorial Sloan-Kettering Cancer Center; 7Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 8Massachusetts General Hospital Cancer Center; 9Stanford Cancer Institute; 10Dana-Farber/Brigham and Women's Cancer Center; 11University of Alabama at Birmingham Comprehensive Cancer Center; 12Roswell Park Cancer Institute; 13The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 14Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 15The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 16UCSF Helen Diller Family Comprehensive Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18City of Hope Comprehensive Cancer Center; 19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 20Duke Cancer Institute; 21University of Michigan Comprehensive Cancer Center; 22Vanderbilt-Ingram Cancer Center; 23Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and 24National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/12/4/473.full.pdf
Web Search
http://dx.doi.org/10.6004/jnccn.2014.0053DOI Listing
April 2014

Practical radiation oncology for extremity sarcomas.

Surg Oncol Clin N Am 2013 Jul 13;22(3):433-43. Epub 2013 Mar 13.

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2013.02.004DOI Listing
July 2013

Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.

Sarcoma 2012 29;2012:680708. Epub 2012 Apr 29.

Department of Radiation Oncology, Duke University Medical Center, Box 91006, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/680708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350993PMC
August 2012

Retraction in part: A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Mol Cancer Ther 2012 May 29;11(5):1214-5. Epub 2012 Mar 29.

Duke Institute for Genome Sciences and Policy, Duke University and Division of Medical Oncology, Department of Medicine, Duke University, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0210DOI Listing
May 2012

Targeted therapy in sarcoma: should we be lumpers or splitters?

Am Soc Clin Oncol Educ Book 2012 :652-7

From the Duke Cancer Institute, Duke University Medical Center, Durham, NC; Mount Sinai School of Medicine, New York, NY; Dana Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.204DOI Listing
April 2016

Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?

Authors:
Richard F Riedel

Semin Oncol 2011 Oct;38 Suppl 3:S30-42

Duke Sarcoma Program, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2011.09.003DOI Listing
October 2011

Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches.

Authors:
Richard F Riedel

Cancer 2012 Mar 11;118(6):1474-85. Epub 2011 Aug 11.

Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26415DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412982PMC
March 2012

Primary meningeal rhabdomyosarcoma.

Sarcoma 2011 23;2011:312802. Epub 2011 Jun 23.

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2011/312802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3137955PMC
November 2011

Emerging therapeutic targets for soft tissue sarcoma.

Curr Oncol Rep 2011 Aug;13(4):350-8

Divisions of Hematology, Medical Oncology, Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-011-0175-yDOI Listing
August 2011

Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.

Proc Natl Acad Sci U S A 2009 Mar 11;106(13):5312-7. Epub 2009 Mar 11.

Institute for Genome Sciences and Policy, Department of Medicine, and Institute for Statistics and Decision Sciences, Duke University, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0900827106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664027PMC
March 2009

The clinical management of chondrosarcoma.

Curr Treat Options Oncol 2009 Apr 24;10(1-2):94-106. Epub 2009 Feb 24.

Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11864-009-0088-2
Publisher Site
http://dx.doi.org/10.1007/s11864-009-0088-2DOI Listing
April 2009

A genomic approach to identify molecular pathways associated with chemotherapy resistance.

Mol Cancer Ther 2008 Oct;7(10):3141-9

Duke Institute for Genome Sciences and Policy, Duke University, 2175 CIEMAS Building, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0642DOI Listing
October 2008

A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

J Thorac Oncol 2007 Jun;2(6):520-5

Ruth and Herman Albert Thoracic Oncology Program, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318060107cDOI Listing
June 2007

Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care.

J Thorac Oncol 2006 Sep;1(7):692-6

Department of Medicine, Durham Veterans Affairs Medical Center and Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
September 2006

Genomic signatures to guide the use of chemotherapeutics.

Nat Med 2006 Nov 22;12(11):1294-300. Epub 2006 Oct 22.

Duke Institute for Genome Sciences and Policy, Duke University, Box 3382, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nm1491
Publisher Site
http://dx.doi.org/10.1038/nm1491DOI Listing
November 2006

Thymoma: benign appearance, malignant potential.

Oncologist 2006 Sep;11(8):887-94

DUMC 3305, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.11-8-887DOI Listing
September 2006

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.

Future Oncol 2005 Aug;1(4):461-6

Duke University Medical Center, Division of Hematology, Department of Medicine, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.1.4.461DOI Listing
August 2005

Small-cell lung cancer: a review of clinical trials.

Semin Thorac Cardiovasc Surg 2003 Oct;15(4):448-56

Division of Medical Oncology and Transplantation, Herman and Ruth Albert Thoracic Oncology Program, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/s1043-0679(03)00098-4DOI Listing
October 2003